Filing summary
Entity discrepancy: Although the request metadata names Solana Co, the supplied Form 10-Q is for Helius Medical Technologies, Inc. (Nasdaq: HSDT). This summary reflects the filing provided, for the quarter ended September 30, 2023, filed November 9, 2023. Amounts are U.S. dollars unless stated otherwise.
Business context and reporting period
Helius is a neurotechnology company commercializing its PoNS device and therapy for certain neurological deficits. The product is sold in the U.S. and Canada; U.S. prescriptions began in March 2022 and commercial sales in April 2022. The filing reports unaudited third-quarter and nine-month results through September 30, 2023.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $143,000 | $196,000 | $510,000 | $505,000 |
| Gross profit (loss) | $(44,000) | $95,000 | $17,000 | $192,000 |
| Operating loss | $(3.153 million) | $(4.853 million) | $(10.182 million) | $(12.847 million) |
| Net loss | $(3.663 million) | $(1.030 million) | $(7.805 million) | $(9.186 million) |
| Basic and diluted loss per share | $(5.49) | $(2.90) | $(13.60) | $(53.77) |
- At September 30, cash and cash equivalents were $6.596 million, versus $14.549 million at December 31, 2022. The company also reported $435,000 of warrant proceeds receivable; management described cash, cash equivalents, and that receivable as approximately $7.0 million.
- Working capital was $7.141 million, down from $14.709 million at year-end 2022. Current assets were $8.576 million and current liabilities $1.435 million.
- Total liabilities were $5.833 million, including a $4.239 million derivative warrant liability and $70,000 of operating lease liabilities. The balance sheet reports no conventional borrowings.
- For the first nine months, operating cash use was $8.382 million, investing cash use was $26,000, and financing cash provided was $455,000. Cash declined by $7.953 million.
Material changes versus prior comparable periods
- Q3 revenue fell $53,000 year over year, mainly as U.S. product sales decreased to $60,000 from $139,000 after the Patient Therapy Access Program ended June 30, 2023. Canadian sales rose to $72,000 from $56,000.
- Q3 gross profit shifted to a $44,000 loss from $95,000 profit, reflecting lower sales volume and reduced absorption of fixed manufacturing overhead. Nine-month gross profit fell to $17,000 from $192,000 as cost of revenue increased to $493,000 from $313,000.
- Nine-month revenue was nearly flat, but operating expenses declined by $2.840 million to $10.199 million. Lower SG&A and R&D costs contributed to the smaller operating loss.
- Q3 net loss widened despite lower operating expenses. A $393,000 loss from remeasurement of the warrant derivative liability replaced a $5.489 million gain in Q3 2022. For the nine months, derivative remeasurement contributed $2.051 million of income, down from $5.489 million.
- Operating cash use improved by $3.785 million year over year, while financing cash flow fell substantially from the prior year, which included significant offering proceeds.
Outlook, commentary, risks, and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year after the financial statements are filed. It expects ongoing losses and cash outflows, and said existing capital resources were expected to fund operations through 2023; additional equity or debt funding would be needed thereafter. Failure to raise capital could require reducing operations or could lead to cessation of operations.
- Commercialization and reimbursement: PoNS is not covered by CMS or other U.S. third-party payers. The company resubmitted an application for unique HCPCS codes and expected a preliminary CMS response in Q4 2023. Management anticipated broad payer coverage could take at least 24 months; self-pay patients were expected to remain the primary sales source before coverage.
- Manufacturing transition: The company began moving production from Key Tronic to Minnetronix in Q3. It expected most of the transition by year-end 2023 and full completion by mid-2024, while warning that delays or disruptions could harm the business.
- Funding and market risks: The company cited uncertain capital-market conditions, inflation, higher interest rates, supply-chain and logistics constraints, labor shortages, and geopolitical conflicts as risks to costs, operations, and access to capital.
- Impairment and warrants: A $159,000 Q3 impairment charge related to machinery affected by the planned manufacturing-partner change. The $4.239 million derivative liability relates to public warrants and is remeasured at fair value, creating potentially volatile non-operating results. The warrants’ exercise price was reset after the 1-for-50 reverse stock split.
- Capital actions: The company sold shares under a $2.0 million at-the-market program, reporting approximately $300,000 net proceeds through September 30. Public warrant exercises generated $642,000 in proceeds, of which $435,000 remained receivable from the transfer agent at quarter-end.
- The company reported no material legal proceedings and said disclosure controls and procedures were effective at quarter-end.
Important facts for investors to verify
- Confirm current cash, warrant proceeds collected, subsequent financing, and the company’s updated liquidity runway given the stated going-concern uncertainty.
- Track U.S. and Canadian PoNS sales, customer concentration, and whether sales can grow after the access program ended; two customers accounted for 91% of Q3 product sales.
- Check CMS’s response and progress toward reimbursement, HCPCS coding, commercial insurance coverage, and clinical evidence requirements.
- Monitor manufacturing transition milestones, product availability, costs, and any resulting impairment or supply disruption.
- Review warrant-related dilution and derivative-liability remeasurement, as well as the post-split share count. The filing reports 687,799 shares outstanding at September 30 and 708,247 at November 3, 2023.